Will Apremilast/Apremilast tablets rebound? The truth turns out to be this!

Apremilast is an important oral non-biological agent currently used in the clinical treatment of plaque psoriasis and psoriatic arthritis (PSA). It inhibits phosphodiesterase 4 (PDE4), thereby reducing the release of inflammatory factors such as TNF-α, IL-17, IL-23, etc., to achieve anti-inflammatory and immunomodulatory effects. Many patients' conditions improve significantly during use, but they are also worried about whether there will be a "rebound" once the medication is stopped, that is, the symptoms will recur or even worsen.

Judging from the existing clinical data, apremilast itself does not trigger a rebound reaction in the immune system and is not strictly a "rebound drug" in the traditional sense. However, because it does not have a lasting immune remodeling effect, once the drug is discontinued, the inflammatory state of some patients may gradually rise within weeks to months, manifesting as symptoms such as reappearance of skin lesions and worsening joint pain. This situation is actually more consistent with "relapse" rather than "rebound." Clinical studies in the United States and Europe have shown that about one-third to half of patients experience varying degrees of disease regression within 3-6 months of stopping the drug, but the vast majority of patients can still regain good control after restarting apremilast.

It is worth emphasizing that apremilast does not cause drug dependence and will not induce disease progression due to discontinuation of the drug. Therefore, if the drug needs to be discontinued, it is recommended to conduct a gradual evaluation under the guidance of a doctor. Some patients can reduce the risk of recurrence by extending the dosing interval or combining other non-systemic drugs for transitional treatment. In short, the condition may relapse after discontinuation of Apremilast, but this is not a true rebound reaction. Scientific use of medication and reasonable evaluation of the timing of discontinuation can minimize the probability of recurrence.

Reference materials:https://go.drugbank.com/drugs/DB05676